Advertisement

ASO Author Reflections: Factors that Predict Performance of Sentinel Lymph Node Biopsy and the Association with Improved Survival for Melanoma Patients Who Have Nodal Staging

  • Timothy D. Murtha
  • Dale Han
ASO Author Reflections
  • 39 Downloads

Notes

Disclosure

The authors have no conflict of interest to disclose

References

  1. 1.
    Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370:599–609.CrossRefGoogle Scholar
  2. 2.
    Wong SL, Faries MB, Kennedy EB, et al. Sentinel lymph node biopsy and management of regional lymph nodes in melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2018;36:399–413.CrossRefGoogle Scholar
  3. 3.
    Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376:2211–22.CrossRefGoogle Scholar
  4. 4.
    Leiter U, Stadler R, Mauch C, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy-positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2016;17:757–67.CrossRefGoogle Scholar
  5. 5.
    Murtha TD, Han G, Han D. Predictors for use of sentinel node biopsy and the association with improved survival in melanoma patients who have nodal staging. Ann Surg Oncol. 2018;25:903–11.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  1. 1.Section of Surgical Oncology, Department of SurgeryYale School of MedicineNew HavenUSA
  2. 2.Division of Surgical Oncology, Department of SurgeryOregon Health and Science UniversityPortlandUSA

Personalised recommendations